TY - JOUR
T1 - Pathological angiogenesis
T2 - mechanisms and therapeutic strategies
AU - Dudley, Andrew C.
AU - Griffioen, Arjan W.
N1 - Funding Information: KWF Kankerbestrijding, VU2018–11651. ACD is supported by grants from the the National Institutes of Health/National Cancer Institute (2RO1 CA177875 and RO1 CA2558451) and funds from the Emily Couric Cancer Center at the University of Virginia. Publisher Copyright: © 2023, The Author(s).
PY - 2023/8
Y1 - 2023/8
N2 - In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-existing ones, is an essential process for growth and development. Different mechanisms such as vasculogenesis, sprouting, intussusceptive, and coalescent angiogenesis, as well as vessel co-option, vasculogenic mimicry and lymphangiogenesis, underlie the formation of new vasculature. In many pathological conditions, such as cancer, atherosclerosis, arthritis, psoriasis, endometriosis, obesity and SARS-CoV-2(COVID-19), developmental angiogenic processes are recapitulated, but are often done so without the normal feedback mechanisms that regulate the ordinary spatial and temporal patterns of blood vessel formation. Thus, pathological angiogenesis presents new challenges yet new opportunities for the design of vascular-directed therapies. Here, we provide an overview of recent insights into blood vessel development and highlight novel therapeutic strategies that promote or inhibit the process of angiogenesis to stabilize, reverse, or even halt disease progression. In our review, we will also explore several additional aspects (the angiogenic switch, hypoxia, angiocrine signals, endothelial plasticity, vessel normalization, and endothelial cell anergy) that operate in parallel to canonical angiogenesis mechanisms and speculate how these processes may also be targeted with anti-angiogenic or vascular-directed therapies.
AB - In multicellular organisms, angiogenesis, the formation of new blood vessels from pre-existing ones, is an essential process for growth and development. Different mechanisms such as vasculogenesis, sprouting, intussusceptive, and coalescent angiogenesis, as well as vessel co-option, vasculogenic mimicry and lymphangiogenesis, underlie the formation of new vasculature. In many pathological conditions, such as cancer, atherosclerosis, arthritis, psoriasis, endometriosis, obesity and SARS-CoV-2(COVID-19), developmental angiogenic processes are recapitulated, but are often done so without the normal feedback mechanisms that regulate the ordinary spatial and temporal patterns of blood vessel formation. Thus, pathological angiogenesis presents new challenges yet new opportunities for the design of vascular-directed therapies. Here, we provide an overview of recent insights into blood vessel development and highlight novel therapeutic strategies that promote or inhibit the process of angiogenesis to stabilize, reverse, or even halt disease progression. In our review, we will also explore several additional aspects (the angiogenic switch, hypoxia, angiocrine signals, endothelial plasticity, vessel normalization, and endothelial cell anergy) that operate in parallel to canonical angiogenesis mechanisms and speculate how these processes may also be targeted with anti-angiogenic or vascular-directed therapies.
KW - Angiogenesis
KW - Anti-angiogenesis
KW - Endothelial cells
KW - Immunotherapy
KW - Vascular biology
KW - Vascular targeting
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85152581320&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/37060495
U2 - https://doi.org/10.1007/s10456-023-09876-7
DO - https://doi.org/10.1007/s10456-023-09876-7
M3 - Review article
C2 - 37060495
SN - 0969-6970
VL - 26
SP - 313
EP - 347
JO - Angiogenesis
JF - Angiogenesis
IS - 3
ER -